Algorae Pharmaceuticals (ASX:1AI) is working with the Victorian Center for Functional Genomics (VCFG) at Peter MacCallum Cancer Center to validate artificial intelligence-predicted drug interactions through screening, according to a Thursday filing with the Australian bourse.
The study will assess 24 drug candidates using VCFG's advanced screening platform to confirm drug combinations' efficacy across four cancer cell lines, the filing said.
The data analysis is expected to be completed within three weeks of each screen run, with the full dataset expected to be completed within six months, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.